



3007 Rec'd PCT/PTO 18 APR 2005
MAIL STOP PCT
Attorney Docket No. 26549U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

ZIV et al.

International Application No. PCT/IL03/00463

Serial No. 10/516,616

International Filing Date: 3 June 2003(03.06.2003)

Filed: December 3, 2004

For: **AGENTS FOR IMAGING AND DIAGNOSTIC METHODS USING THEM**

TRANSMITTAL LETTER

Commissioner of Patents
P.O. Box 1450
Alexandria, Va 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- (1) Transmittal Letter;
- (2) Information Disclosure Statement;
- (3) PTO Form 1449 with 15 references;
- (4) Copies of 15 cited references.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,

NATH & ASSOCIATES PLLC

By: _____

Gary M. Nath
Registration No. 26,965
Jerald L. Meyer
Registration No. 41,194
Customer No. 20529

Date: April 18, 2005
NATH & ASSOCIATES PLLC
1030 15th Street NW - 6th Floor
Washington, D.C. 20005
GMN/JLM/ng/IDS_TR_mailstop

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

ZIV et al.

International Application No. PCT/IL03/00463

Serial No. 10/516,616

International Filing Date: 3 June 2003(03.06.2003)

Filed: December 3, 2004

For: AGENTS FOR IMAGING AND DIAGNOSTIC METHODS USING THEM

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. § 1.97-1.98. Please note the following particulars:

[NOTE: One only of items a, b, c, and d must be checked.]

- [X] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.
- [] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311.

The enclosed statement is accompanied by [check one]:

- [] i. a certification in part (e) below as specified in 37 C.F.R. § 1.97(e), or
- [] ii. a check in the amount required by 37 C.F.R. § 1.17(p).
- [] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311, but before payment of the issue fee.
- [] Certification report(e) below; and
- [] a check in the amount as required by § 1.17(p).
- [] d. The enclosed statement is being filed pursuant to 37 C.F.R. § 1.97(i), for placement in the file.
- [] e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

☐ I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

☐ I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

☐ Appropriate certification is attached.

☒ f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

☒ g. Copies of the documents are attached herewith with a completed Form PTO-1449.

or

☐ Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:
or Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
NATH & ASSOCIATES PLLC

By: _____

Gary M. Nath
Registration No. 26,965
Jerald L. Meyer
Registration No. 41,194
Customer No. 20529

Date: April 18, 2005

NATH & ASSOCIATES PLLC
1030 15th Street, N.W., 6th Floor
Washington, D.C. 20005
Tel. (202) 775-8383
Fax. (202) 775-8396
GMN/JLM/ng (IDSstatement_GMNJLM)

FORM PTO-1449				Atty Docket 26549U		Serial No. 10/516,616	
				Applicant ZIV et al.			
				Filing Date December 3, 2005		Group Art Unit Not Yet Assigned	
INFORMATION DISCLOSURE CITATION							
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Sub-Class	Trans-lation
	AA	EP 0451 824 A2	16.10.91	EP			N/A
	AB	WO 02/46147 A2	13.06.02	WIPO			N/A
	AC	WO 02/074346 A2	26.09.02	WIPO			N/A
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
	AD	Chiotellis, E. et al. "Structure-Activity Relationships of Some Technetium-99m Labeled [(Thioethyl)amino] Carboxylates", <u>J. Med. Chem.</u> , vol.25 pp.1370-1374, 1982.					
	AE	Lazarides, E. et al. "Fluorescent localization of membrane sites in glycerinated chicken skeletal muscle fibers and the relationship of these sites to the protein composition of the Z disc", <u>Proc.Natl.Acad.Sci.USA</u> , vol.75(8) pp.3683-3687, 1978.					
	AF	Bever, E.M. et al. "Lipid translocation across the plasma membrane of mammalian cells", <u>Biochimica et Biophysica Acta</u> , vol.1439 pp.317-330, 1999.					
	AG	Bombeli, T. et al. "Apoptotic Vascular Endothelial Cells Become Procoagulant", <u>Blood</u> , vol.89(7) pp.2429-2442, 1997.					
	AH	Bratton, D.L. et al. "Appearance of Phosphatidylserine on Apoptotic Cells Requires Calcium-mediated Nonspecific Flip-Flop and is Enhanced by Loss of the Aminophospholipid Translocase", <u>The Journal of Biological Chemistry</u> , vol.272(42) pp.26159-26165, 1997.					
	AI	Bursch, W. et al. "Cell death by apoptosis and its protective role against disease", <u>TIPS</u> , vol.13 pp.245-251, 1992.					
	AJ	Kockx, M.M. et al. "Apoptosis in atherosclerosis: beneficial or detrimental?", <u>Cardiovascular Research</u> , vol.45 pp.736-746, 2000.					
	AK	Mallat, Z. et al. "Colocalization of CPP-32 With Apoptotic Cells in Human Atherosclerotic Plaques", <u>Circulation</u> , vol.96 pp.424-428, 1997.					
	AL	Martin, S.J. et al. "Early Redistribution of Plasma Membrane Phosphatidylserine is a General Feature of Apoptosis Regardless of the Initiating Stimulus: Inhibition by Overexpression of Bcl-2 and Abl", <u>J. Exp. Med.</u> , vol.182 pp.1545-1556, 1995.					
	AM	Sims, P.J. et al. "Unraveling the Mysteries of Phospholipid Scrambling", <u>Thromb Haemost</u> , vol.86 pp.266-275, 2001.					
	AN	Stary, H.C. et al. "A Definition of Advanced Types of Atherosclerotic Lesions and a Histological Classification of Atherosclerosis", <u>Circulation</u> , vol.92 pp.1355-1374, 1995.					
	AO	Van den Eijnde, S.M. et al. "Phosphatidylserine plasma membrane asymmetry in vivo: a pancellular phenomenon which alters during apoptosis", <u>Cell Death and Differentiation</u> , vol.4 pp.311-316, 1997.					
Examiner				Date Considered			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							